| Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma RA Kyle, ED Remstein, TM Therneau, A Dispenzieri, PJ Kurtin, ... New England Journal of Medicine 356 (25), 2582-2590, 2007 | 1099 | 2007 |
| Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia TD Shanafelt, XV Wang, NE Kay, CA Hanson, S O’Brien, J Barrientos, ... New England Journal of Medicine 381 (5), 432-443, 2019 | 740 | 2019 |
| Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival AJ Novak, JR Darce, BK Arendt, B Harder, K Henderson, W Kindsvogel, ... Blood 103 (2), 689-694, 2004 | 684 | 2004 |
| Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma A Dispenzieri, RA Kyle, JA Katzmann, TM Therneau, D Larson, J Benson, ... Blood, The Journal of the American Society of Hematology 111 (2), 785-789, 2008 | 511 | 2008 |
| Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997 MR Grever, DM Lucas, GW Dewald, DS Neuberg, JC Reed, S Kitada, ... Journal of Clinical Oncology 25 (7), 799-804, 2007 | 451 | 2007 |
| Cloning and regulation of cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis. DF Jelinek, S Andersson, CA Slaughter, DW Russell Journal of Biological Chemistry 265 (14), 8190-8197, 1990 | 435 | 1990 |
| Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study A Dispenzieri, JA Katzmann, RA Kyle, DR Larson, LJ Melton, CL Colby, ... The Lancet 375 (9727), 1721-1728, 2010 | 417 | 2010 |
| Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B … NE Kay, SM Geyer, TG Call, TD Shanafelt, CS Zent, DF Jelinek, ... Blood 109 (2), 405-411, 2007 | 357 | 2007 |
| Regulated expression of BAFF-binding receptors during human B cell differentiation JR Darce, BK Arendt, X Wu, DF Jelinek The Journal of Immunology 179 (11), 7276-7286, 2007 | 308 | 2007 |
| Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival AJ Novak, RJ Bram, NE Kay, DF Jelinek Blood, The Journal of the American Society of Hematology 100 (8), 2973-2979, 2002 | 307 | 2002 |
| Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia TD Shanafelt, TE Witzig, SR Fink, RB Jenkins, SF Paternoster, SA Smoley, ... Journal of Clinical Oncology 24 (28), 4634-4641, 2006 | 305 | 2006 |
| Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B‐cell chronic lymphocytic … GW Dewald, SR Brockman, SF Paternoster, ND Bone, JR O'Fallon, ... British journal of haematology 121 (2), 287-295, 2003 | 293 | 2003 |
| Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome AJ Novak, DM Grote, M Stenson, SC Ziesmer, TE Witzig, TM Habermann, ... Blood 104 (8), 2247-2253, 2004 | 285 | 2004 |
| VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia YK Lee, ND Bone, AK Strege, TD Shanafelt, DF Jelinek, NE Kay Blood 104 (3), 788-794, 2004 | 280 | 2004 |
| IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells JW Lee, HY Chung, LA Ehrlich, DF Jelinek, NS Callander, GD Roodman, ... Blood 103 (6), 2308-2315, 2004 | 279 | 2004 |
| Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1. DF Jelinek, PE Lipsky Journal of immunology (Baltimore, Md.: 1950) 139 (9), 2970-2976, 1987 | 254 | 1987 |
| Analysis of clonal B‐cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B‐chronic lymphocytic leukaemia DF Jelinek, RC Tschumper, SM Geyer, ND Bone, GW Dewald, ... British journal of haematology 115 (4), 854-861, 2001 | 252 | 2001 |
| CD4+ T-cell immune response to large B-cell non-Hodgkin’s lymphoma predicts patient outcome SM Ansell, M Stenson, TM Habermann, DF Jelinek, TE Witzig Journal of Clinical Oncology 19 (3), 720-726, 2001 | 213 | 2001 |
| Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma JR Cerhan, SM Ansell, ZS Fredericksen, NE Kay, M Liebow, TG Call, ... Blood, The Journal of the American Society of Hematology 110 (13), 4455-4463, 2007 | 212 | 2007 |
| Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia TD Shanafelt, TG Call, CS Zent, B LaPlant, DA Bowen, M Roos, ... Journal of Clinical Oncology 27 (23), 3808, 2009 | 211 | 2009 |
